Back to Search
Start Over
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
- Source :
-
European urology [Eur Urol] 2002 Nov; Vol. 42 (5), pp. 481-90. - Publication Year :
- 2002
-
Abstract
- Objectives: To compare the efficacy of bicalutamide monotherapy to maximal androgen blockade in advanced prostatic cancer.<br />Patients and Methods: Previously untreated patients with histologically proven stage C or D (American Urological Association Staging System) disease were randomly allocated to either bicalutamide (B) or goserelin plus flutamide (G+F). After disease progression, patients treated with B were assigned to castration. The primary endpoint for this trial was overall survival. Prostate cancer-specific survival and progression were included among secondary endpoints.<br />Results: In total 108 patients received B and 112 received G+F. At a median follow-up time of 54 months (range 1-89), 151 patients progressed and 113 died. There was no significant difference in the duration of either progression-free or overall survival. Hazards of progression, death and cancer-specific death, corrected by disease stage, tumor grade and baseline PSA level, showed that patients initially assigned to B had a higher risk of progression but a comparable risk of death and cancer-specific death with the exception of patients with G3 tumors who had an increased risk of death).<br />Conclusions: In patients with well or moderately well differentiated tumors, B monotherapy followed by castration may offer the same survival chance as maximal androgen deprivation. In those patients it thus represents a reasonable choice that can avoid the side effects of androgen deprivation for considerable periods of time.
- Subjects :
- Aged
Aged, 80 and over
Disease Progression
Flutamide administration & dosage
Goserelin administration & dosage
Humans
Male
Middle Aged
Nitriles
Prostate-Specific Antigen
Prostatic Neoplasms pathology
Survival Analysis
Tosyl Compounds
Treatment Outcome
Anilides therapeutic use
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0302-2838
- Volume :
- 42
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- European urology
- Publication Type :
- Academic Journal
- Accession number :
- 12429158
- Full Text :
- https://doi.org/10.1016/s0302-2838(02)00435-9